Poolbeg Pharma (POLB) Competitors GBX 3.15 -0.10 (-3.08%) As of 07/3/2025 11:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock POLB vs. ORPH, REDX, ETX, SBTX, COS, C4XD, DDDD, TRX, FUM, and OKYOShould you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Tissue Regenix Group (TRX), Futura Medical (FUM), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry. Poolbeg Pharma vs. Its Competitors Open Orphan Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Tissue Regenix Group Futura Medical OKYO Pharma Open Orphan (LON:ORPH) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability. Does the media favor ORPH or POLB? In the previous week, Open Orphan had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Open Orphan and 0 mentions for Poolbeg Pharma. Open Orphan's average media sentiment score of 0.48 beat Poolbeg Pharma's score of 0.00 indicating that Open Orphan is being referred to more favorably in the media. Company Overall Sentiment Open Orphan Neutral Poolbeg Pharma Neutral Which has stronger valuation & earnings, ORPH or POLB? Open Orphan has higher revenue and earnings than Poolbeg Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpen Orphan£34.71M0.00N/AN/AN/APoolbeg PharmaN/AN/A-£4.50B-£851.820.00 Is ORPH or POLB more profitable? Open Orphan's return on equity of 0.00% beat Poolbeg Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Open OrphanN/A N/A N/A Poolbeg Pharma N/A -32.56%-21.33% Do institutionals & insiders believe in ORPH or POLB? 1.2% of Poolbeg Pharma shares are owned by institutional investors. 24.7% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryOpen Orphan beats Poolbeg Pharma on 5 of the 8 factors compared between the two stocks. Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POLB vs. The Competition Export to ExcelMetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£16.19M£127.99M£5.50B£2.96BDividend YieldN/A3.74%5.38%5.02%P/E Ratio0.003.4227.60146.59Price / SalesN/A4,131.75369.54240,167.53Price / Cash2.1113.1936.6327.97Price / Book0.0043.018.055.30Net Income-£4.50B-£92.79M£3.18B£5.90B7 Day Performance-5.03%2.65%2.82%0.92%1 Month Performance-3.29%2.48%3.69%5.20%1 Year Performance-76.32%178.35%35.41%80.76% Poolbeg Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POLBPoolbeg PharmaN/AGBX 3.15-3.1%N/A-76.2%£16.19MN/A0.0012Gap UpORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035News CoverageHigh Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 16.620.0%N/A+94.1%£37.98M£1.56M-10.2211COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106TRXTissue Regenix GroupN/AGBX 30+1.7%N/A-57.3%£27.05M£31.98M-30.97120News CoverageFUMFutura MedicalN/AGBX 7.98-5.3%N/A-78.4%£24.88M£8.68M-6.5912Gap UpOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007News CoverageGap Down Related Companies and Tools Related Companies ORPH Competitors REDX Competitors ETX Competitors SBTX Competitors COS Competitors C4XD Competitors DDDD Competitors TRX Competitors FUM Competitors OKYO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:POLB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free POLB Stock Alerts